Stelexis Therapeutics
Biotechnology, 780 3rd Ave, New York, 10017, United States, 1-10 Employees
Phone Number: 21********
Who is STELEXIS THERAPEUTICS
Stelexis is a Deerfield founded and solely funded New York-based cancer therapeutics company with a mission of transforming cancer therapeutics paradigm and patient care, through the disc...
Read More
-
Headquarters: 780 3rd Ave, New York, New York, 10017, United States
-
Date Founded: 2017
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from STELEXIS THERAPEUTICS
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Stelexis Therapeutics
Answer: Stelexis Therapeutics's headquarters are located at 780 3rd Ave, New York, 10017, United States
Answer: Stelexis Therapeutics's phone number is 21********
Answer: Stelexis Therapeutics's official website is https://stelexis.com
Answer: Stelexis Therapeutics's revenue is $1 Million to $5 Million
Answer: Stelexis Therapeutics's SIC: 2834
Answer: Stelexis Therapeutics's NAICS: 325412
Answer: Stelexis Therapeutics has 1-10 employees
Answer: Stelexis Therapeutics is in Biotechnology
Answer: Stelexis Therapeutics contact info: Phone number: 21******** Website: https://stelexis.com
Answer: Stelexis is a Deerfield founded and solely funded New York-based cancer therapeutics company with a mission of transforming cancer therapeutics paradigm and patient care, through the discovery and development of novel drugs. Stelexis proprietary platform is focused on identifying, isolating and studying the earliest definable stem and progenitor cells, which harbor clonal properties and pre-cancerous alterations, that drive the formation of primary and recurrent human tumors. Stelexis utilizes this powerful platform as a target identification engine and drug discovery and development tool to address unmet needs in multiple cancer indications. Deerfield founded Stelexis Therapeutics in 2017 together with scientific founders, Drs. Ulrich Steidl, Evripidis Gavathiotis, Amit Verma and Roman Perez-Soler of Albert Einstein College of Medicine, Montefiore Medicine, New York and Dr. Derrick Rossi of Boston Childrens Hospital, Harvard Medical School.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month